| 摘要 |
PURPOSE:To obtain the novel modifier for treating thrombosis, etc., by replacing a specific site of a tissue plasminogen-activating factor by a urea plasminogen activating factor sequence, replacing a N-binding sugar chain sequence, reducing side effects and prolonging half time in blood. CONSTITUTION:In this novel t-PA modifier, at least one part of an amino acid sequence corresponding to 276-306 position of amino acid sequence of natural type t-PA in an amino acid sequence of tissue plasminogen activating factor (t-PA) is replaced by an amino acid sequence of urea plasminogen-activating factor (UK) having corresponding relation shown in the formula and further, at least one of N-bound sugar saccharide-added consensus sequences corresponding to 117-119 position, 184-186 position and 448-450 position of natural type t-PA is replaced by a sequence other than N-bond added consensus sequence. The novel t-PA modifier is useful as a therapeutic agent for thrombosis capable of reducing a side effect of systemic bleeding tendency and prolonging half-life period in blood. |
